Related Experiment Video
Updated: Feb 28, 2026

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Mass spectrometry as a tool for biomarkers searching in gynecological oncology
Paulina Banach1, Wiktor Suchy1, Paweł Dereziński2
1Department of Gynecology, Obstetrics and Gynecologic Oncology, Division of Gynecologic Oncology, Poznan University of Medical Sciences, Polna 33, 60-535 Poznań, Poland.
Abstract:
Tumors of the female reproductive tract are an important target for the development of diagnostic, prognostic and therapeutic strategies. Recent research has turned to proteomics based on mass spectrometry techniques, to achieve more effective diagnostic results. Mass spectrometry (MS) enables identification and quantification of multiple molecules simultaneously in a single experiment according to mass to charge ratio (m/z). Several proteomic strategies may be applied to establish the function of a particular protein/peptide or to identify a novel disease and specific biomarkers related to it. Therefore, MS could facilitate treatment in patients with tumors by helping researchers discover new biomarkers and narrowly targeted drugs. This review presents a comprehensive discussion of mass spectrometry as a tool for biomarkers searching that may lead to the discovery of easily available diagnostic tests in gynecological oncology with emphasis on clinical proteomics over the past decade. The article provides an insight into different MS based proteomic approaches.
Insights
Mass spectrometry (MS) aids gynecological oncology by identifying protein biomarkers for improved diagnostics and targeted therapies. This review highlights MS-based proteomics for discovering new diagnostic tests and treatments.
Area of Science:
- Gynecological Oncology
- Proteomics
- Biomarker Discovery
Background:
- Tumors of the female reproductive tract require advanced diagnostic, prognostic, and therapeutic strategies.
- Mass spectrometry (MS) offers a powerful platform for simultaneous identification and quantification of multiple molecules.
- Clinical proteomics has emerged as a key area for advancing gynecological cancer research.
Purpose of the Study:
- To review the application of mass spectrometry in biomarker searching for gynecological oncology.
- To provide insight into various MS-based proteomic approaches.
- To emphasize the potential of MS in developing novel diagnostic tests and targeted therapies.
Main Methods:
- Review of mass spectrometry techniques in proteomics.
- Analysis of MS-based proteomic strategies for biomarker discovery.
- Focus on clinical proteomics applications in gynecological oncology over the past decade.
Main Results:
- Mass spectrometry enables simultaneous identification and quantification of molecules.
- Proteomic strategies can identify novel disease biomarkers and protein functions.
- MS facilitates the discovery of new biomarkers and targeted drugs for cancer treatment.
Conclusions:
- Mass spectrometry is a crucial tool for biomarker discovery in gynecological oncology.
- MS-based proteomics can lead to the development of accessible diagnostic tests.
- Advancements in MS are pivotal for improving patient treatment outcomes.
Related Concept Videos
MALDI-TOF Mass Spectrometry
Peptide Identification Using Tandem Mass Spectrometry
This technique helps gather information regarding the protein from which the peptide was obtained and to study the peptides’ amino acid sequence. Identifying peptides from a complex mixture is an important component of the growing field of...
Mass Spectrometry: Complex Analysis
GC–MS is a powerful hyphenated method commonly used in forensics and environmental...

